Skip to main content
Premium Trial:

Request an Annual Quote

Biotage to Cut 50 Jobs, Transfer Instrument Production

NEW YORK (GenomeWeb News) – Biotage said today that it will transfer its instrument production operations to a contract manufacturer, which will result in 50 jobs being cut from the firm.

The Uppsala, Sweden-based life science tools firm said that it would move its instrument production from its current facilities in Charlottesville, Va., to an unnamed contract manufacturer. The instruments made at that facility are primarily for purification applications. A small portion of the firm's consumables also are made at the Virginia facility, but production of those products will be moved to Biotage's facility in Cardiff, Wales, which already manufactures the majority of its consumables.

"By moving production from Charlottesville, we achieve considerable efficiency gains and reduce susceptibility to changes in demand," Biotage President and CEO Torben Jorgensen said in a statement.

Biotage expects to complete the transfer of production to the contractor by the end of this year.

The firm did not provide an estimate of savings from the outsourcing and job cuts.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.